ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc., an emerging leader in next generation femtosecond laser technology for refractive cataract surgery, today is pleased to announce world renowned ophthalmologist Richard L. Lindstrom, M.D. has joined the company’s board of directors effective immediately.
"For nearly 40 years, Dr. Lindstrom has been a driving force in ophthalmology as a premier clinician, innovator, and strategic thought-leader dedicated to advancing the science and technologies of vision," said Nicholas Curtis, CEO of LENSAR, Inc. "I have known Dr. Lindstrom personally for almost 30 years and am thrilled to evolve our relationship into a productive partnership focused on LENSAR’s growth and success in the refractive cataract sector."
Dr. Lindstrom, founder and attending surgeon of Minnesota Eye Consultants and Adjunct Professor Emeritus at the University of Minnesota Department of Ophthalmology, is a board-certified ophthalmologist and internationally-recognized leader in corneal, cataract, refractive and laser surgery. He has been at the forefront of ophthalmology's evolutionary changes throughout his career, as a recognized researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon. Dr. Lindstrom has served as both medical officer and board member to many of the breakthrough ophthalmic technologies of the past two decades and is a sought-after consultant to the entire ophthalmic industry.
“The refractive cataract business is poised for disruption and explosive growth over the next few years as the global population ages and patient demands for high performance visual outcomes increase with the availability of new pharmaceuticals and medical devices,” said Dr. Lindstrom. “I firmly believe LENSAR leads the field in innovation, speed to market and customer support. I am proud to take part in their evolution to capitalize on their technology and drive the sector forward.”
About LENSAR, Inc.
LENSAR, Inc., is a global leader in next generation femtosecond cataract laser technology for refractive cataract surgery. The LENSAR Laser System with Streamline IV offers cataract surgeons automation and customization for their astigmatism treatment planning and other essential steps of the refractive cataract surgery procedure with the highest levels of precision, accuracy, and efficiency. These features assist surgeons in managing astigmatism treatment for optimal overall visual outcomes.
The LENSAR Laser System has been cleared by the U.S. Food and Drug Administration for anterior capsulotomy, lens fragmentation, and corneal and arcuate incisions. For other indications, it is an investigational device limited by U.S. law to investigational use only.
LENSAR, Inc. is a wholly-owned subsidiary of PDL BioPharma, Inc. (NASDAQ: PDLI) For more information, please visit www.lensar.com.
